TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06196580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: repaglinide; midazolam; SHR4640 placebo
Description: repaglinide; midazolam; SHR4640 placebo
Study: NCT05911022

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: three times per day for three days and subsequently twice per day for four days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Formula
Description: oral sachets once daily for two weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol
Description: the Egyptian Supreme Council of University Hospitals (Vitamin C 500 mg twice daily, Vitamin D3 2000-4000 IU/day, Zinc 75 mg once daily for two weeks
Study: NCT06230796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-cycling
Description: 30 minutes of active leg cycling with or without FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM-cycling
Description: 30 minutes of active leg cycling with SHAM FES applied to the paretic rectus femoris of quadriceps and to the biceps femoris and semitendinosus muscles and gluteus maximus, 3 times/weeks for 8 weeks. During training, participants will be seated on a FES-Cycle (Hepha Bike, Kurage): a cyclo-ergometer (Technogym) combined with a 8 channel controlled stimulator (Motimove-8).
Study: NCT06399757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-5125
Description: APL-5125 is an oral drug (capsule) taken daily in 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-5125
Description: APL-5125 is an oral drug (capsule) taken daily in 28-day cycles
Study: NCT06181955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy
Description: The ESWT was performed by an ESWT instrument (Chattanooga) once a week for four consecutive weeks (a total of four sessions).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: Conventional physical therapy consisted of ultrasound therapy and three types of knee-strengthening exercises.
Study: NCT05098483

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration in primary molars by using MTA
Description: Regenerative endodontic procedure in nonvital primary molars using MTA capping material

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regeneration in primary molars by using biodentine
Description: Regenerative endodontic treatment in primary molars with biodentine as capping material

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Root canal treatment in primary molars
Description: Removal of pulp tissue from the canals of primary molars
Study: NCT05303454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cartoons
Description: cartoons were found to be effective in reducing children's pain and fear levels.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: musical-moving toys
Description: musical-moving toys were found to be effective in reducing children's pain and fear levels.
Study: NCT05334979

Intervention type: OTHER
Group type: OTHER
Intervention: Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic
Description: Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks.

Intervention type: OTHER
Group type: OTHER
Intervention: Kidney stones Normal controls Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic
Description: Consuming a special drink (sodium oxalate) during an all day visit to the University of Chicago research clinic~Subjects in both arms will be asked to partake in the same activities, as follows: The day before presenting to the research clinic subjects will collect urine at home. Subjects will will come in to the research clinic at the University of Chicago in Hyde Park, where they will spend most of the day. We will give them a special liquid that contains oxalate, and they will receive a specially prepared breakfast that is low in oxalate and citrate. After this, we will collect urine and blood throughout the day. While at the clinic, subjects will also receive specially prepared snacks.
Study: NCT05384951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB + Vitamin D3
Description: The supplement will be taken orally twice daily. Participants will take 2 blended HMB + Vitamin D3 tablets in the morning and 2 tablets in the evening for 12 weeks.
Study: NCT04444830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprix
Description: Intranasal Ketorolac - used as directed for an appropriate, previously established indication
Study: NCT04727515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl 2µg/kg intravenously and maintained with isoflurane
Description: Anesthesia will be induced using titration of intravenous propofol till loss of verbal contact and fentanyl 2µg/kg intravenously and maintained with isoflurane (end tidal up to 1.5%), oxygen in air 50:50 via a laryngeal mask.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary nerve Block
Description: Axillary block will be performed using ultrasound technique. Patients will receive an axillary block under ultrasound guidance using a linear 5-12 MHz probe.
Study: NCT04909788

Intervention type: BEHAVIORAL
Intervention: a long-distance running (over 3 km)
Description: Complete a long distance running（over 3 km） within the specified time (30 minutes)
Study: NCT05529654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella 5.5 with SmartAssist
Description: For subjects enrolled in the Trial, the Impella 5.5 will be placed intra-operatively during the index cardiac surgical procedure
Study: NCT06408844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavior change program implemented with 5A model
Description: According to the 5A model, the personal action plan includes the following items:~1. List specific goals by behavioral period~2. List obstacles and strategies to address them~3. Determine follow-up plan~4. Sharing the plan with the child and family In accordance with this plan, it is aimed to increase physical activity behavior in the classroom and during online meetings for 8 weeks. Additionally, after the training, motivational reminders will be held at regular intervals until the 28th week.
Study: NCT06053021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel, cilostazol, and dipyridamole
Description: Participants will be prescribed antiplatelet agents including aspirin, clopidogrel, cilostazol, and dipyridamole.
Study: NCT05524701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction and Normal Sleep
Description: The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Restriction and Normal Sleep
Description: The intervention will consist of either sleep restriction (4 hours per night, 3 am to 7 am) or normal sleep (8 hours per night 11 pm to 7 am) for a duration of two nights.
Study: NCT05350891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic surgery
Description: endoscopic surgery combined with adjuvant immunotherapy with/without chemotherapy
Study: NCT05735470

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: antibacterial bone traction needles
Description: Whether to use bone traction needles containing antibacterial coatings
Study: NCT06113978

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic sympathectomy
Description: Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, managed by thoracoscopic bilateral simultaneous sympathectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic sympathotomy
Description: Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, who underwent thoracoscopic bilateral simultaneous sympathotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracoscopic sympathetic chain clipping
Description: Medical file records of patients of both sexes, below 18 years of age, suffering from significant bilateral palmar hyperhidrosis, treated by thoracoscopic bilateral simultaneous sympathetic chain clipping.
Study: NCT06055335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium flow anesthesia
Description: Group MeFA; after reaching the MAC 1 value with 4lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, medium flow anesthesia was started with 2 lt/min 50% O2 - 50% air with MAC 1 concentration desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal flow anesthesia
Description: Group MiFA; after reaching the MAC 1 value with 4 lt/min 50% O2 - 50% air and 8% desflurane with remifentanil infusion, minimal flow anesthesia was started with 0.50 lt/min 50% O2 - 50% air with MAC 1 concentration of desflurane. The vaporizer was closed at the end of the last suture, and the flow was increased to 80% oxygen at 6 lt/min.
Study: NCT04661254

Intervention type: OTHER
Group type: OTHER
Intervention: Lymphapheresis
Description: - From the blood product of lymphapheresis: Autologous naïve regulatory CD45RA+CD4+CD25+FoxP3+ T lymphocytes (Tregs) selected and amplified ex vivo; obtained by selection and sorting of CD4+CD25 +CD127lowCD45RA+ cells, derived from lymphapheresis and amplified ex vivo for 10 +/- 1 days, under cGMP condition in the presence of IL2 and Rapamycin
Study: NCT05615935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experiential HIV Testing
Description: The content of experiential HIV Testing includes HIV testing, counselling, and education and discussion.
Study: NCT04825197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poractant Alfa Intratracheal Suspension [Curosurf]
Description: up to 4 doses (100 mg Kg) of Poractant alfa every 12 hours; each dose preceded by a recruitment manoeuvre in HFOV.
Study: NCT05445960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tourniquet
Description: This arm will have a tourniquet placed about the thigh and inflated to 250mmHg for the duration of ankle fracture surgery or 2 hours, whichever is shorter.
Study: NCT06453057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT307 injection
Description: GT307 injection to treat solid tumours
Study: NCT05268627

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: endoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: endoscopy
Study: NCT04809753

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eustachian tube dilation
Description: Dilation of the eustachian tube with an endovascular balloon
Study: NCT06409832

Intervention type: DRUG
Intervention: Rimegepant 75 mg
Description: Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention

Intervention type: DRUG
Intervention: Rimegepant 75 mg
Description: Patients using Rimegepant 75 mg orally disintegrating tablet every other day as migraine prevention
Study: NCT06388044

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy (ACT) is a third-wave cognitive behavioral therapy. ACT aims to increase psychological flexibility through six core processes: acceptance, cognitive defusion, present-moment awareness, self as context, values, and committed action.
Study: NCT06087419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide
Description: 30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: 400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: 0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
Study: NCT05451927

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phaseolus Vulgaris
Description: Weight loss

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04801940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Apixaban 2.5mg orally twice daily for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 40mg orally once daily for 12 months.
Study: NCT06196411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-oriented Training
Description: Task-oriented training will be applied to study group 5 days a week, for a total of 6 weeks, in addition to Bobath training. Task-oriented training will consist of performing the lying, sitting, standing and walking exercises by performing tasks for specific goals. Exercises will be perform by accomplishing tasks such as touching the ball with the upper or lower extremities, reaching for the ball, crossing various tracks to move blocks from one place to another, walking through obstacles or climbing stairs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bobath Training
Description: Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bobath Training
Description: Bobath Concept includes sensory, perceptual and adaptive exercises aimed at improving function through mobilisation, weight-bearing, practicing more normal movement patterns and performing more efficient, less effortful tasks.
Study: NCT06067854

Intervention type: PROCEDURE
Intervention: the standard procedure - without regional anaesthesia
Description: the standard procedure - without regional anaesthesia

Intervention type: PROCEDURE
Intervention: infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
Description: infraorbital peripheral blockade with or without nasal peripheral blockade according to the preference of the anesthesiologist and surgeon
Study: NCT06491043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UMC119-06-05
Description: Human Umbilical Cord Derived-Mesenchymal Stem Cells

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UMC119-06-05
Description: Human Umbilical Cord Derived-Mesenchymal Stem Cells
Study: NCT06053710

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable bioimpedance sensor
Description: The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable bioimpedance sensor
Description: The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
Study: NCT05849285

Intervention type: OTHER
Intervention: TLC Clinic
Description: Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team

Intervention type: OTHER
Intervention: TLC Clinic
Description: Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team

Intervention type: OTHER
Intervention: TLC Clinic
Description: Patients of the TLC clinic - receive coordinated multidisciplinary and specialized care from a team
Study: NCT04770077

Intervention type: OTHER
Intervention: Intubation on manikin
Description: Training of medical student to focus on manikin vocal cord before intubation

Intervention type: OTHER
Intervention: Intubation on manikin
Description: Training of medical student to focus on manikin vocal cord before intubation
Study: NCT05879653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: During the induction phase, MK-3475 200 mg will be administered as four cycles of 3-weeks regimen, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle. The treatment and maintenance phases will consist of 9 cycles of one course per 6 weeks, with MK-3475 400 mg administered on Day 1 of each course at Q6W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASG-22CE
Description: During the induction phase, four cycles of 3-weeks regimen are administered, with ASG-22CE 1.25 mg/kg administered on Day 1 and Day 8 of each cycle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maximal TURBT
Description: All participants who were not determined to have PD on imaging during the induction phase should have had a maximal TURBT performed at 13 (± 1week) weeks after the first dose of trial drug.
Study: NCT06491043

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: UMC119-06-05
Description: Human Umbilical Cord Derived-Mesenchymal Stem Cells
Study: NCT05520879

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sharnali 1
Description: The intervention is food product, made from locally available food ingredients in Bangladesh.~Sharnali 1 made from rice, lentil, dried skimmed milk, sugar, vegetable oils and micronutrient premix.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sharnali 2
Description: Sharnali 2 made from chick peas, dried skimmed milk, sugar, vegetable oils and micronutrient premix.
Study: NCT04564131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: * Hands are washed.~* The individual is provided to be in a comfortable position to lie down or to be in a semi-sitting position.~* The toes of the patient are crossed and the patient's feet are placed at our chest level when we sit.~* Depending on the size of the foot, a slightly moisturizing amount of non-allergenic petroleum jelly is taken, and it is spread to provide slipperiness.~* Exercises to warm and relax the feet for five minutes.~* General massage is applied to the whole foot for five minutes.~* Reflexology massage is applied to the application areas for neuropathic pain.~* The individual is helped to take a comfortable position.~* Hands are washed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was performed to reduce pain in the control group
Study: NCT05879653

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiotherapy will be initiated no later than 8 weeks after maximal TUR-BT. In this trial, a total dose of 56 Gy will be delivered using 2 Gy per dose. 40 Gy/20 fr (2 Gy/fr) to the small pelvis followed by 16 Gy /8 fr (2 Gy/fr) to the whole bladder 5 times a week for 5 consecutive days using Three-Dimensional Conformal Radiation Therapy (3D-CRT).
Study: NCT04658589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic versus open distal gastrectomy
Description: Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic versus open distal gastrectomy
Description: Laparoscopic versus open distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer
Study: NCT06438601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (omafilcon A)
Description: 15 minutes of daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (comfilcon A)
Description: 15 minutes of daily wear
Study: NCT04731857

Intervention type: GENETIC
Intervention: Retrospective data analysis
Description: The outlined evaluation contributes to the improvement of molecular genetic diagnostics in patient care - for example when which diagnostics can be sensibly recommended for patients with which indications or not. Diagnostic gaps can be systematically evaluated and specifically addressed in the future. This potentially affects every examination assignment for current and future patients. In addition, the evaluation of the PRSs for example, can contribute significantly to the timely introduction to routine diagnostics. For familial breast cancer, according to the guidelines, there may be very specific preventive measures. Estimates currently assume up to 5% of patients, which would mean up to 25 cases per year with a potentially adapted management for patients with the question of a tumor disease alone.
Study: NCT05781048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-6209
Description: HRS-6209